SciSparc is a specialty clinical-stage pharmaceutical company focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

The company is currently engaged in drug development programs based on THC and/or non-psychoactive cannabidiol (CBD), including SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimers disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.